Skip to content

Pacira BioSciences, Inc. PCRX Property, plant and equipment at cost

Property, plant and equipment at cost at other companies

Avanos Medical logo
Avanos MedicalAVNS

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s property, plant and equipment at cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s property, plant and equipment at cost?
Pacira BioSciences, Inc. (PCRX) reported property, plant and equipment at cost of $280.99M in Q1 2026.
How has Pacira BioSciences, Inc.'s property, plant and equipment at cost changed year-over-year?
Pacira BioSciences, Inc.'s property, plant and equipment at cost decreased by 7.6% year-over-year, from $304.23M to $280.99M.
What is the long-term trend for Pacira BioSciences, Inc.'s property, plant and equipment at cost?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s property, plant and equipment at cost has grown at a 5.3% compound annual growth rate (CAGR), from $215.05M to $278.39M.